Commit To Buy Flexion Therapeutics At $10, Earn 17% Annualized Using Options

Investors considering a purchase of Flexion Therapeutics, Inc. ( FLXN) shares, but tentative about paying the going market price of $17.89/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the May 2017 put at the $10 strike, which has a bid at the time of this writing of 80 cents. Collecting that bid as the premium represents a 8% return against the $10 commitment, or a 17% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

START SLIDESHOW:
Top YieldBoost Puts of Stocks with Recent Secondaries »

Selling a put does not give an investor access to FLXN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $10 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Flexion Therapeutics, Inc. sees its shares decline 44.1% and the contract is exercised (resulting in a cost basis of $9.20 per share before broker commissions, subtracting the 80 cents from $10), the only upside to the put seller is from collecting that premium for the 17% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for Flexion Therapeutics, Inc., and highlighting in green where the $10 strike is located relative to that history:

If you liked this article you might like

'Date' These Potential Biotech Winners

'Date' These Potential Biotech Winners

2 Biotechs That Could Flex Their Muscles

Biotech Movers: Ocular, Alder, Flexion

2 Recovering Biotech Names With Room to Run